ClinicalTrials.gg
CompletedNCT01251614Updated Sep 25, 2017Results posted

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

A Phase 3 interventional study of Adalimumab and Methotrexate in Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-09-25.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
29th of 48
114 · median 148
Started
2010
with 3 others
Phase 3
26 of 48
1 open now
Registered
16th of 48
by date
Lead sponsor
6 of 48
AbbVie (prior sponsor, Abbott)

Among the 48 studies testing adalimumab in Psoriasis, this one is the 29th largest by enrollment, is one of 4 that started in 2010, is one of 26 in phase 3, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

This study will compare how well adalimumab works versus methotrexate (MTX) in children with moderate to severe psoriasis in the short term. It will also study how safe and how well adalimumab works in the long term and how long disease response can be maintained after stopping therapy.

Read the detailed description

The study had a 30-day screening period and a multi-period study design, as described below:

Period A - Primary Treatment Phase: Participants were randomized to receive adalimumab 0.8 mg/kg, adalimumab 0.4 mg/kg, or MTX in 1:1:1 ratio for 16 weeks.

Period B - Treatment Withdrawal Phase: Responders were withdrawn from active treatment and monitored for loss of disease control for up to 36 weeks.

Period C - Re-Treatment Phase: Participants who had experienced loss of disease control in Period B were re-treated with adalimumab for 16 weeks.

Period D - Long-Term Follow-Up Phase: Participants received adalimumab or were observed off-treatment (if disease remained under control) for 52 weeks.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Randomized
  • Double-blind
  • Chronic plaque psoriasis
  • Pediatric
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥ 4 years and \< 18 years of age;
  2. Subject weighs ≥ 13 kg;
  3. Subject must have failed to respond to topical therapy;
  4. Subject must need systemic treatment to control his/her disease and meet one of the following:

    • Physician's Global Assessment (PGA) ≥ 4
    • Body surface area (BSA) involved > 20%
    • Very thick lesions with BSA > 10%
    • Psoriasis Area and Severity Index (PASI) > 20
    • PASI > 10 and at least one of the following:

      • Active psoriatic arthritis unresponsive to non- anti-inflammatory drugs (NSAIDs)
      • facial involvement
      • Clinically relevant genital involvement
      • Clinically relevant hand and/or foot involvement
      • Children's Dermatology Life Quality Index (CDLQI) > 10
  5. If subject is \< 12 years of age and resides in a geographic region where heliotherapy is practical, subject must have failed to respond, be intolerant, or have a to heliotherapy, or is not a suitable candidate for heliotherapy;
  6. If ≥ 12 years of age, subject must have failed to respond, be intolerant, or have a contraindication to phototherapy, or is not a suitable candidate for phototherapy;
  7. Subject must have a clinical diagnosis of psoriasis for at least 6 months as determined by the subject's medical history and confirmation of diagnosis through physical examination by the Investigator;
  8. Subject must have stable plaque psoriasis for at least 2 months prior to Baseline

Exclusion criteria

Exclusion Criteria:

  1. Prior biologic use other than prior treatment with etanercept;
  2. Treatment with etanercept therapy within 4 weeks prior to the Baseline visit; 3. Methotrexate (MTX) use within the past year or prior MTX use at any time where the subject did not respond, or did not tolerate MTX;
  1. for treatment with MTX during the study; 5. Erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication exacerbated psoriasis or new onset guttate psoriasis; 6. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline Visit or oral anti-infectives within 14 days prior to the Baseline Visit; 7. Treatment of psoriasis with topical therapies such as , vitamin D analogs, or retinoids within 7 days prior to the Baseline visit; 8. Treatment of psoriasis with ultraviolet (UV)B phototherapy, excessive sun exposure, or the use of tanning beds within 7 days prior to the Baseline visit; 9. Treatment of psoriasis with ultraviolet A with psoralen (PUVA) phototherapy, non-biologic systemic therapies for the treatment of psoriasis, or systemic therapies known to improve psoriasis within 14 days prior to the Baseline visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Adalimumab 0.4 mg/kg

    In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.

    Biological: Adalimumab · Drug: Placebo to Methotrexate

  • Experimental
    Adalimumab 0.8 mg/kg

    In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.

    Biological: Adalimumab · Drug: Placebo to Methotrexate

  • Active comparator
    Methotrexate

    Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.

    Drug: Methotrexate · Biological: Placebo to Adalimumab

Interventions

  • BiologicalAdalimumab

    Adalimumab by subcutaneous injection every other week (eow)

    Also known as: ABT-D2E7, Humira

  • Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.

  • BiologicalPlacebo to Adalimumab

    A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.

  • DrugPlacebo to Methotrexate

    Orally once a week

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in PASI score at Week 16.

    Time frame: Baseline and Week 16

  2. Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 16

    The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a PASI 90 Response at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score at Week 16.

    Time frame: Baseline and Week 16

  2. Percentage of Participants Who Achieved a PASI 100 Response at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score at Week 16.

    Time frame: Baseline and Week 16

  3. Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16

    The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline and Week 16

  4. Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 16

    The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).

    Time frame: Baseline and Week 16

  5. Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Upon Re-Treatment in Period C

    The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \< 5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

    Time frame: Period C, Week 16

  6. Time to Loss of Disease Control for Participants Who Entered Period B

    Loss of disease control was defined as a worsening of PGA scores in comparison to Week 16 of Period A by at least 2 grades after treatment withdrawal. The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. Scores range from 0 (no evidence of scaling, erythema, or plaque elevation) to 5 (very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation). Participants who did not lose disease control in period B continued off drug into period D and were observed off-drug until they finally lost disease control or until the end of the 52 weeks of period D.

    Time frame: Period B (36 weeks) and Period D (52 weeks)

  7. Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Over Time

    The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

    Time frame: Period A, Weeks 4, 8 and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  8. Percentage of Participants Achieving a PGA of "Cleared" (0) Over Time

    The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) is reported.

    Time frame: Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  9. Percentage of Participants Who Achieved a PASI 50 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is at least a 50% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline, Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  10. Percentage of Participants Who Achieved a PASI 75 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is at least a 75% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline, Period A, Weeks 4, 8, and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  11. Percentage of Participants Who Achieved a PASI 90 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline, Period A, Weeks 4, 8 and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  12. Percentage of Participants Who Achieved a PASI 100 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline, Period A, Weeks 4, 8, and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  13. Percent Change From Baseline in PASI Score Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).

    Time frame: Baseline, Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52

  14. Change From Baseline in CDLQI Over Time

    The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline, Period A, Weeks 4, and 8, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52

  15. Percentage of Participants With CDLQI = 0 Over Time

    The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired and a score of 0 indicates no impairment in quality of life.

    Time frame: Period A, Weeks 4, 8 and 16, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52

  16. Time to PASI 50/75/90/100 Response in Period A

    Participants who did not have a response during Period A were censored.

    Time frame: Period A, 16 weeks

  17. Change From Baseline in PedsQL Over Time

    The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).

    Time frame: Baseline, Period A, Weeks 4 and 8, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52

  18. Change From Baseline in the Children's Depression Inventory: Short (CDI:S)

    The CDI:S is a short 10-item self-rated symptom-oriented scale used to screen for depressive symptoms. CDI:S scores range from 0 to 100, with a lower score indicating fewer depressive symptoms.

    Time frame: Baseline, Period A, Weeks 4, 8, and 16

07

Results

Posted Apr 4, 2017

Participant flow

Participants were enrolled at 38 sites in Belgium, Canada, Chile, Czech Republic, Germany, Hungary, Italy, Mexico, Netherlands, Poland, Spain, Switzerland, and Turkey.

Participant flow — Overall Study
MilestoneMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Started373938
Entered period b131823
Entered period c81119
Entered period d363636
Completed342630
Not completed3138
Withdrew: Adverse event101
Withdrew: Lack of efficacy194
Withdrew: Clearing of psoriatic lesions100
Withdrew: Pregnancy002
Withdrew: Loss of disease control010
Withdrew: Withdrawal by subject021
Withdrew: Lost to follow-up010

Outcome measures

PrimaryPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in PASI score at Week 16.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 1632.443.657.9
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · Chi-squared · p = 0.027 · Difference: -25.5 · 95% CI -47.2 to -3.7
PrimaryPercentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 16

The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 16
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 1640.541.060.5
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · Chi-squared · p = 0.083 · Difference: -20.0 · 95% CI -42.2 to 2.2
SecondaryPercentage of Participants Who Achieved a PASI 90 Response at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score at Week 16.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 90 Response at Week 16
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Percentage of Participants Who Achieved a PASI 90 Response at Week 1621.630.828.9
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · Chi-squared · p = 0.466 · Difference: -7.3 · 95% CI -26.9 to 12.3
SecondaryPercentage of Participants Who Achieved a PASI 100 Response at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score at Week 16.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 100 Response at Week 16
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Percentage of Participants Who Achieved a PASI 100 Response at Week 162.710.318.4
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · Fisher Exact · p = 0.056 · Difference: -15.7 · 95% CI -29.1 to -2.3
SecondaryChange From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16

The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16
units on a scaleMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16-5.0 ± 7.11-4.9 ± 6.16-6.6 ± 6.22
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · ANOVA · p = 0.304 · Difference: 1.61 · 95% CI -1.48 to 4.70
SecondaryChange From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 16

The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 16
units on a scaleMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 161.9 ± 10.419.5 ± 12.2510.8 ± 15.38
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · ANOVA · p = 0.005 · Difference: -8.88 · 95% CI -14.94 to -2.82
SecondaryPercentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Upon Re-Treatment in Period C

The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \< 5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

Time frame:
Period C, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Upon Re-Treatment in Period C
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Upon Re-Treatment in Period C62.527.352.6
Statistical analysis
  • Methotrexate vs Adalimumab 0.4 mg/kg vs Adalimumab 0.8 mg/kg · Chi-squared · p = 0.113 · Difference: -28.3 · 95% CI -60.6 to 4.0
SecondaryTime to Loss of Disease Control for Participants Who Entered Period B

Loss of disease control was defined as a worsening of PGA scores in comparison to Week 16 of Period A by at least 2 grades after treatment withdrawal. The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. Scores range from 0 (no evidence of scaling, erythema, or plaque elevation) to 5 (very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation). Participants who did not lose disease control in period B continued off drug into period D and were observed off-drug until they finally lost disease control or until the end of the 52 weeks of period D.

Time frame:
Period B (36 weeks) and Period D (52 weeks)
Reported as:
Median · days
Time to Loss of Disease Control for Participants Who Entered Period B
daysMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Time to Loss of Disease Control for Participants Who Entered Period B184 (84 to 335)217 (56 to 551)118 (79 to 194)
Statistical analysis
  • Methotrexate vs Adalimumab 0.8 mg/kg · Log Rank · p = 0.343 · Hazard ratio (hr): 1.45 · 95% CI 0.66 to 3.17
  • Adalimumab 0.4 mg/kg vs Adalimumab 0.8 mg/kg · Log Rank · p = 0.276 · Hazard ratio (hr): 1.51 · 95% CI 0.71 to 3.21
SecondaryPercentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Over Time

The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

Time frame:
Period A, Weeks 4, 8 and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 48.120.528.9
Period A, Week 88.135.944.7
Period A, Week 1118.930.847.4
Period C, Week 00.00.00.0
Period C, Week 1662.527.352.6
Period D, Week 030.619.438.9
Period D, Week 1677.838.950.0
Period D, Week 2869.450.063.9
Period D, Week 4069.450.061.1
Period D, Week 5275.050.055.6
SecondaryPercentage of Participants Achieving a PGA of "Cleared" (0) Over Time

The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) is reported.

Time frame:
Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PGA of "Cleared" (0) Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 40.02.62.6
Period A, Week 80.012.85.3
Period A, Week 110.010.310.5
Period A, Week 168.112.818.4
Period C, Week 00.00.00.0
Period C, Week 1625.09.115.8
Period D, Week 08.35.611.1
Period D, Week 1625.011.125.0
Period D, Week 2833.316.722.2
Period D, Week 4033.316.727.8
Period D, Week 5241.725.025.0
SecondaryPercentage of Participants Who Achieved a PASI 50 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is at least a 50% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline, Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 50 Response Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 416.241.052.6
Period A, Week 840.556.465.8
Period A, Week 1151.461.571.1
Period A, Week 1654.166.778.9
Period C, Week 062.590.952.6
Period C, Week 1687.590.989.5
Period D, Week 052.863.975.0
Period D, Week 1691.769.488.9
Period D, Week 2888.972.286.1
Period D, Week 4091.763.983.3
Period D, Week 5291.766.777.8
SecondaryPercentage of Participants Who Achieved a PASI 75 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is at least a 75% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline, Period A, Weeks 4, 8, and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 75 Response Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 40.015.423.7
Period A, Week 813.538.547.4
Period A, Week 1121.643.660.5
Period C, Week 037.518.221.1
Period C, Week 1675.054.578.9
Period D, Week 030.627.850.0
Period D, Week 1686.150.061.1
Period D, Week 2880.658.377.8
Period D, Week 4077.852.875.0
Period D, Week 5286.147.272.2
SecondaryPercentage of Participants Who Achieved a PASI 90 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline, Period A, Weeks 4, 8 and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 90 Response Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 40.05.15.3
Period A, Week 82.720.523.7
Period A, Week 112.728.228.9
Period C, Week 00.00.010.5
Period C, Week 1662.527.357.9
Period D, Week 025.016.736.1
Period D, Week 1663.936.138.9
Period D, Week 2855.633.341.7
Period D, Week 4055.636.147.2
Period D, Week 5266.733.344.4
SecondaryPercentage of Participants Who Achieved a PASI 100 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline, Period A, Weeks 4, 8, and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 100 Response Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 40.00.02.6
Period A, Week 80.05.15.3
Period A, Week 110.05.110.5
Period C, Week 00.00.00.0
Period C, Week 1625.09.115.8
Period D, Week 08.35.611.1
Period D, Week 1613.911.125.0
Period D, Week 2827.813.919.4
Period D, Week 4030.613.922.2
Period D, Week 5241.725.022.2
SecondaryPercent Change From Baseline in PASI Score Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).

Time frame:
Baseline, Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in PASI Score Over Time
percent changeMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 4-14.0 ± 36.71-36.9 ± 38.62-48.3 ± 33.96
Period A, Week 8-30.6 ± 45.89-48.8 ± 44.74-60.3 ± 35.98
Period A, Week 11-36.6 ± 51.69-51.4 ± 50.19-62.8 ± 38.02
Period A, Week 16-42.8 ± 54.24-52.4 ± 51.79-65.6 ± 39.44
Period C, Week 0-59.0 ± 20.61-65.3 ± 12.16-45.8 ± 39.64
Period C, Week 16-87.1 ± 16.47-74.5 ± 17.79-69.3 ± 69.79
Period D, Week 0-41.8 ± 54.99-46.8 ± 49.27-61.5 ± 42.96
Period D, Week 16-82.3 ± 31.38-66.9 ± 33.51-74.5 ± 37.44
Period D, Week 28-81.0 ± 35.86-65.8 ± 36.99-81.5 ± 22.06
Period D, Week 40-83.0 ± 31.94-64.6 ± 37.46-82.1 ± 23.99
Period D, Week 52-86.3 ± 28.92-58.7 ± 53.21-80.1 ± 24.17
SecondaryChange From Baseline in CDLQI Over Time

The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline, Period A, Weeks 4, and 8, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52
Reported as:
Mean · units on a scale
Change From Baseline in CDLQI Over Time
units on a scaleMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 4-2.9 ± 5.24-3.9 ± 5.22-4.9 ± 5.80
Period A, Week 8-4.0 ± 6.44-4.1 ± 6.29-5.5 ± 5.66
Period C, Week 0-6.1 ± 4.55-4.7 ± 9.08-6.1 ± 6.92
Period C, Week 4-9.8 ± 3.92-5.5 ± 7.24-7.0 ± 6.63
Period D, Week 0-5.6 ± 7.55-5.5 ± 5.95-6.8 ± 6.70
Period D, Week 11-8.5 ± 5.37-6.8 ± 7.07-7.4 ± 6.21
Period D, Week 28-8.3 ± 5.93-6.8 ± 7.91-8.4 ± 6.72
Period D, Week 52-8.4 ± 6.08-6.6 ± 8.12-8.2 ± 6.75
SecondaryPercentage of Participants With CDLQI = 0 Over Time

The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired and a score of 0 indicates no impairment in quality of life.

Time frame:
Period A, Weeks 4, 8 and 16, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With CDLQI = 0 Over Time
percentage of participantsMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 45.45.110.5
Period A, Week 810.812.85.3
Period A, Week 1610.820.523.7
Period C, Week 00.036.421.1
Period C, Week 412.536.431.6
Period D, Week 016.722.227.8
Period D, Week 1125.016.733.3
Period D, Week 2830.622.230.6
Period D, Week 5241.716.733.3
SecondaryTime to PASI 50/75/90/100 Response in Period A

Participants who did not have a response during Period A were censored.

Time frame:
Period A, 16 weeks
Reported as:
Median · days
Time to PASI 50/75/90/100 Response in Period A
daysMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
PASI 5076 (56 to 112)55 (28 to 115)30 (28 to 77)
PASI 75116 (111 to NA)107 (56 to NA)59 (53 to NA)
PASI 90NA (112 to NA)NA (78 to NA)NA (76 to NA)
PASI 100NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in PedsQL Over Time

The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).

Time frame:
Baseline, Period A, Weeks 4 and 8, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52
Reported as:
Mean · units on a scale
Change From Baseline in PedsQL Over Time
units on a scaleMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 4-0.8 ± 11.754.9 ± 13.808.1 ± 11.95
Period A, Week 80.5 ± 10.187.0 ± 13.168.8 ± 15.45
Period C, Week 03.0 ± 10.458.9 ± 25.3514.2 ± 20.25
Period C, Week 45.2 ± 11.0811.6 ± 25.1916.3 ± 17.35
Period D, Week 02.3 ± 10.939.4 ± 16.9010.5 ± 15.86
Period D, Week 115.4 ± 10.3612.8 ± 19.0312.0 ± 16.13
Period D, Week 288.0 ± 13.4014.5 ± 20.1913.1 ± 16.23
Period D, Week 528.6 ± 13.9314.0 ± 20.4013.8 ± 15.36
SecondaryChange From Baseline in the Children's Depression Inventory: Short (CDI:S)

The CDI:S is a short 10-item self-rated symptom-oriented scale used to screen for depressive symptoms. CDI:S scores range from 0 to 100, with a lower score indicating fewer depressive symptoms.

Time frame:
Baseline, Period A, Weeks 4, 8, and 16
Reported as:
Mean · units on a scale
Change From Baseline in the Children's Depression Inventory: Short (CDI:S)
units on a scaleMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kg
Period A, Week 40.6 ± 8.85-1.0 ± 6.64-3.6 ± 5.86
Period A, Week 80.2 ± 5.26-1.5 ± 7.52-1.6 ± 5.52
Period A, Week 16-2.0 ± 5.88-3.3 ± 8.12-2.3 ± 6.29

Adverse events

Collected over Period A - up to 16 weeks; Period B - up to 36 weeks; Period C - up to 16 weeks; Period D - up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Methotrexate—0/37 (0%)23/37 (62.2%)
Adalimumab 0.4 mg/kg—3/39 (7.7%)27/39 (69.2%)
Adalimumab 0.8 mg/kg—0/38 (0%)23/38 (60.5%)
Period B: MTX/No Treatment—0/13 (0%)6/13 (46.2%)
Period B: ADA 0.4 mg/kg/No Treatment—0/18 (0%)6/18 (33.3%)
Period B: ADA 0.8 mg/kg/No Treatment—1/23 (4.3%)6/23 (26.1%)
Period C: Adalimumab 0.4 mg/kg—0/11 (0%)5/11 (45.5%)
Period C: Adalimumab 0.8 mg/kg—0/27 (0%)16/27 (59.3%)
Period D: Adalimumab 0.4 mg/kg—0/13 (0%)8/13 (61.5%)
Period D: Adalimumab 0.8 mg/kg—5/87 (5.7%)64/87 (73.6%)
Most frequent serious events
Most frequent serious events
EventMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgPeriod B: MTX/No TreatmentPeriod B: ADA 0.4 mg/kg/No TreatmentPeriod B: ADA 0.8 mg/kg/No TreatmentPeriod C: Adalimumab 0.4 mg/kgPeriod C: Adalimumab 0.8 mg/kgPeriod D: Adalimumab 0.4 mg/kgPeriod D: Adalimumab 0.8 mg/kg
Haemorrhagic Ovarian CystReproductive system and breast disorders0/370/390/380/130/181/230/110/270/130/87
Gastrointestinal InfectionInfections and infestations0/371/390/380/130/180/230/110/270/130/87
Hand FractureInjury, poisoning and procedural complications0/371/390/380/130/180/230/110/270/130/87
AgitationPsychiatric disorders0/371/390/380/130/180/230/110/270/130/87
Chest PainGeneral disorders0/370/390/380/130/180/230/110/270/131/87
FallInjury, poisoning and procedural complications0/370/390/380/130/180/230/110/270/131/87
Tendon InjuryInjury, poisoning and procedural complications0/370/390/380/130/180/230/110/270/131/87
Eye NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/370/390/380/130/180/230/110/270/131/87
Rash Maculo-PapularSkin and subcutaneous tissue disorders0/370/390/380/130/180/230/110/270/131/87
Most frequent other events
Showing 10 of 50
Most frequent other events
EventMethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgPeriod B: MTX/No TreatmentPeriod B: ADA 0.4 mg/kg/No TreatmentPeriod B: ADA 0.8 mg/kg/No TreatmentPeriod C: Adalimumab 0.4 mg/kgPeriod C: Adalimumab 0.8 mg/kgPeriod D: Adalimumab 0.4 mg/kgPeriod D: Adalimumab 0.8 mg/kg
NasopharyngitisInfections and infestations7/3710/398/380/131/184/231/115/273/1325/87
HeadacheNervous system disorders4/377/396/381/132/181/230/113/271/1322/87
CoughRespiratory, thoracic and mediastinal disorders1/374/391/380/132/180/232/111/271/134/87
Upper Respiratory Tract InfectionInfections and infestations6/374/392/380/132/181/230/113/270/1313/87
NauseaGastrointestinal disorders4/373/392/380/130/180/230/112/271/1310/87
Back PainMusculoskeletal and connective tissue disorders0/371/392/380/130/180/230/113/270/131/87
Abdominal PainGastrointestinal disorders4/371/391/380/130/180/230/110/270/134/87
InfluenzaInfections and infestations0/370/391/380/130/180/230/110/270/139/87
FatigueGeneral disorders2/374/390/380/130/180/230/112/270/134/87
GastroenteritisInfections and infestations3/370/392/380/130/180/231/110/270/131/87

Baseline characteristics

Intent-to-treat population included all randomized participants

Age, Continuous
Age, Continuous(years)MethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgTotal
Mean13.4 ± 3.4912.6 ± 4.4313.0 ± 3.2913.0 ± 3.76
Sex: Female, Male
Sex: Female, Male(Participants)MethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgTotal
Female26182165
Male11211749
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgTotal
White343435103
Black0000
Asian2215
American Indian/Alaska Native0000
Native Hawaiian or other Pacific Islander0000
Other1225
Mutli Race0101
Psoriasis Area and Severity Index (PASI)
Psoriasis Area and Severity Index (PASI)(units on a scale)MethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgTotal
Mean19.2 ± 10.0216.9 ± 5.7618.9 ± 10.0318.3 ± 8.78
Physician's Global Assessment of Psoriasis
Physician's Global Assessment of Psoriasis(Participants)MethotrexateAdalimumab 0.4 mg/kgAdalimumab 0.8 mg/kgTotal
Cleared0000
Minimal0101
Mild1337
Moderate19181754
Marked17151749
Severe0213
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Papp K, Thaci D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017 Jul 1;390(10089):40-49. doi: 10.1016/S0140-6736(17)31189-3. Epub 2017 May 4. PubMed 28478975 ↗
  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018 Oct;201:166-175.e3. doi: 10.1016/j.jpeds.2018.05.042. Epub 2018 Jul 25. PubMed 30054164 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Dec 2013 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2010
First posted
Dec 2, 2010
Start
Dec 2010
Primary completionActual
Dec 2013
CompletionActual
Feb 2015
Results first posted
Apr 4, 2017
Last update
Sep 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01251614
Responsible party
Sponsor
First posted
Dec 2, 2010
Start date
Dec 2010
Primary completion
Dec 2013
Completion
Feb 2015
Results posted
Apr 4, 2017
Last update
Sep 25, 2017

Study contacts

David A Williams, MD
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion